Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 134Carcinoma, Non-Small-Cell Lung 133Prostatic Neoplasms 87Lung Neoplasms 43Neoplasms 31Squamous Cell Carcinoma of Head and Neck 30Neoplasm Metastasis 29Stomach Neoplasms 26Head and Neck Neoplasms 24Esophageal Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 17Pancreatic Neoplasms 17Ovarian Neoplasms 16Urinary Bladder Neoplasms 13Sarcoma 12Adenocarcinoma of Lung 9Triple Negative Breast Neoplasms 8Fallopian Tube Neoplasms 8Carcinoma, Transitional Cell 8Carcinoma, Ovarian Epithelial 8Adenocarcinoma Of Esophagus 7Recurrence 6Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma 5Breast Neoplasms, Male 5Adenocarcinoma, Bronchiolo-Alveolar 5Laryngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Advanced Solid Tumors 4

Interventions

pertuzumab 3Trastuzumab 3Docetaxel 3tucatinib 1Protons 1Paclitaxel 1Fulvestrant 1Enfuvirtide 1Doxorubicin 1Cyclophosphamide 1Carboplatin 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × HER2-positive Breast Cancer × Docetaxel × Clear all
NCT04957212 2024-07-26

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Cinnagen

Phase 3 Completed
214 enrolled 16 charts
Breast

HER2-positive Breast Cancer

NCT02379585 2018-04-24

STEFNE

Western Regional Medical Center

Phase 1/2 Terminated
8 enrolled 1 chart
Breast

HER2-positive Breast Cancer

NCT02345772 2018-02-20

Neohttp

Western Regional Medical Center

Phase 1/2 Terminated
4 enrolled 1 chart
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡